Cannabinoid Receptor 1 Antagonism Demonstrates High Therapeutic Potential for the Treatment of Primary Sclerosing Cholangitis

Primary sclerosing cholangitis (PSC) is a cholangiopathy that primarily targets cholangiocytes, leading to a ductular reaction, but can have effects on other hepatic cells promoting inflammation and fibrogenesis.1 PSC, although rare, is accompanied by poor prognosis and curative therapeutics are still lacking, thus new treatment options are needed.1